Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy Kasper, S., Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L. I., Haddad, R., Rordorf, T., Kiyota, N., Makoto, T., Lynch, M., Kopit, J., Ferris, R. L. KARGER. 2018: 96
View details for Web of Science ID 000424914300256